CS-AKI

Advertisement

cGxPJobs Banner

Arch Biopartners Gains U.S. IRB Approval for LSALT Phase II

TORONTO, Canada, August 31, 2026 Arch Biopartners Inc. announced that it has received central Institutional Review Board (IRB) approval...

By cGxPwire Editor
September 1, 2026

Read More

Arch Biopartners Expands LSALT Peptide Phase 2 Kidney Injury Trial to U.S.

TORONTO, Canada, August 11, 2026 Arch Biopartners Inc. announced plans to expand its ongoing Phase 2 clinical trial of...

By cGxPwire Editor
August 13, 2026

Read More

Advertisement

cGxPJobs

Directory